Dr. Novack gave a presentation at the Second Annual Myopia Society of Japan on 24 November 2017. This was a joint symposium between the Myopia Society Japan and Eye & Contact Lens. The topic was “Controlling Myopia Progression: Where Do We Stand Today?”. In the concluding presentation of the event, Dr. Novack spoke about what it would in time and risk to develop a novel pharmacological treatment to prevent the development of myopia in children. A photo is provided. Dr. Novack is in the center of the back row. Also shown are Penny Asbell MD (Icahn School of Medicine) and Kazuo Tsubota, M.D. (Keio University).
RxSight, gained US FDA approved for a new type of Intraocular Lens for use after cataract surgery. It can be adjusted AFTER implantation in a patient. I was a founder of this firm which came out of University of California San Francisco (Dan Schwartz, M.D.) (originally named Calhoun Vision) many years ago.
Dr. Novack will be giving several presentations at the Annual Meeting of the American Academy of Ophthalmology in New Orleans in November 2017. On 9 November, he will lead a breakfast with FDA at the OIS AAO. On 11 November, he will give a talk at the Glaucoma Sub-specialty day on New Molecules in Glaucoma Development. On 14 November, he will give a talk on “An update on newly FDA-approved drugs and new drugs in clinical trials” at the Prevent Blindness America symposium. Finally, he will be part of a course on “Empowering glaucoma patients to take better care of themselves.”
Dr. Novack is giving a number of presentations at the upcoming American Academy of Ophthalmology annual meeting in New Orleans. On 9 November, he will chair a breakfast session at [email protected]. On 11 November, he will be presenting “New Molecules in Clinical Development” at the Glaucoma sub-specialty day. On 14 November, he will be presenting a talk on “Newly FDA-approved drugs and new drugs in clinical trials” in a glaucoma meeting sponsored by Prevent Blindness America. Also on 14 November, he will be part of a group of distinguished faculty teaching a course on “Empowering glaucoma patients to take better care of themselves”.
The Dry Eye Workshop II (DEWS II) report, sponsored by the Tear Film and Ocular Surface Society, has now been published in the July 2017 issue of The Ocular Surface. There is an introduction, and 10 sub-committee reports, including the Clinical Trials and Regulatory Sub-Committee report of which Dr. Novack was the chair. This represents over 2 years work by 125+ worldwide researchers and clinicians. It supplants the 2007 report with the latest review of Dry Eye research. #TFOSDEWSII @aao_ophth
Dr. Novack provided an update on novel therapies in pharmacotherapies in Ophthalmology Times. He reviews treatments in all phases of clinical development, and those recently approved. This is from anterior (dry eye, glaucoma) to posterior (wet AMD, etc).
Several groups have declared July 2017 as Dry Eye Awareness Month.
TFOS DEWS II™ highlights will be presented at a July 12 Congressional Briefing entitled Dry Eye: An Updated Definition, A Greater Impact on Vision Health—co-hosted by TFOS and the Alliance for Eye and Vision Research (AEVR)—to be held from 12 Noon – 1:15 pm in Rayburn 2168 (Gold Room). The Briefing will be bookended by a “Test Your Tears” Dry Eye Screening and Dry Eye Researcher Poster Presentation from 11:30 am – 2 pm. The vision community is making Congressional education about dry eye a priority since it impacts healthcare policy, as it is one of the most frequent causes of patient visits to eye care providers, and since federal research funding from the National Institutes of Health (NIH), including its National Eye Institute (NEI), is being used to study dry eye causes and develop treatments.
Also, stay tuned for the TFOS DEWS II report, due 1 July 2017 in The Ocular Surface.
Dr. Novack was a visiting Professor at the University of Wisconsin School of Medicine in Madison in May 2017. He presented a lecture in the Frontiers in Vision Research series about ophthalmic drug development and drug delivery.
Dr. Novack attended the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Baltimore, MD. This was his approximately 33rd ARVO meeting. He presented in the Special Interest Group on the TFOS Dry Eye Workshop II. As well he had two side-by-side posters in a glaucoma poster session- one on an investigational drug, and the other on a recently cleared minimally-invasive glaucoma stent (MIGS). He was also an author on a oral presentation of an investigational drug to treat elevated intraocular pressure.
Dr. Novack in front of his two, side-by-side, posters on glaucoma therapies
TFOS DEWS II Chairs (Dr. Novack is 5th from left)
With recent press releases by the Sponsors, there are at least five ophthalmic New Drug Applications (NDAs) under review by the U.S. FDA at this time (25 April 2017). Some of these were held up for chemistry issues in their original 2016 submissions.